Literature DB >> 9658196

Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines.

M Taglialatela1, A Pannaccione, P Castaldo, G Giorgio, Z Zhou, C T January, A Genovese, G Marone, L Annunziato.   

Abstract

In the current study, the potential blocking ability of K+ channels encoded by the human ether-a-go-go related gene (HERG) by the piperazine H1 receptor antagonist cetirizine has been examined and compared with that of other second-generation antihistamines (astemizole, terfenadine, and loratadine). Cetirizine was completely devoid of any inhibitory action on HERG K+ channels heterologously expressed in Xenopus laevis oocytes in concentrations up to 30 microM. On the other hand, terfenadine and astemizole effectively blocked HERG K+ channels with nanomolar affinities (the estimated IC50 values were 330 and 480 nM, respectively), whereas loratadine was approximately 300-fold less potent (IC50 approximately 100 microM). In addition, in contrast to terfenadine, cetirizine did not show use-dependent blockade. In SH-SY5Y cells, a human neuroblastoma clone that constitutively expresses K+ currents carried by HERG channels (IHERG), as well as in human embryonic kidney 293 cells stably transfected with HERG cDNA, extracellular perfusion with 3 microM cetirizine did not exert any inhibitory action on IHERG. Astemizole (3 microM), on the other hand, was highly effective. Terfenadine (3 microM) caused a marked (approximately 80%) inhibition of IHERG in SH-SY5Y cells, whereas loratadine, at the same concentration, caused a 40% blockade. Furthermore, the application of cetirizine (3 microM) on the intracellular side of the membrane of HERG-transfected human embryonic kidney 293 cells did not affect IHERG, whereas the same intracellular concentration of astemizole caused a complete block. The results of the current study suggest that second-generation antihistamines display marked differences in their ability to block HERG K+ channels. Cetirizine in particular, which possesses more polar and smaller substituent groups attached to the tertiary amine compared with other antihistamines, lacks HERG-blocking properties, possibly explaining the absence of torsade de pointes ventricular arrhythmias associated with its therapeutical use.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658196     DOI: 10.1124/mol.54.1.113

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

Review 1.  Assessing the cardiac safety of ebastine. Epilogue.

Authors:  D J Roberts
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

2.  Differential effects of amino-terminal distal and proximal domains in the regulation of human erg K(+) channel gating.

Authors:  C G Viloria; F Barros; T Giráldez; D Gómez-Varela; P de la Peña
Journal:  Biophys J       Date:  2000-07       Impact factor: 4.033

Review 3.  Cetirizine: a review of its use in children with allergic disorders.

Authors:  C M Spencer; S Noble
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 4.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Visualizing voltage dynamics in zebrafish heart.

Authors:  Hidekazu Tsutsui; Shin-ichi Higashijima; Atsushi Miyawaki; Yasushi Okamura
Journal:  J Physiol       Date:  2010-04-26       Impact factor: 5.182

6.  Non-sedating antihistamines block G-protein-gated inwardly rectifying K+ channels.

Authors:  I-Shan Chen; Chang Liu; Michihiro Tateyama; Izhar Karbat; Motonari Uesugi; Eitan Reuveny; Yoshihiro Kubo
Journal:  Br J Pharmacol       Date:  2019-07-10       Impact factor: 8.739

7.  Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.

Authors:  Elisabetta Poluzzi; I Diemberger; M De Ridder; A Koci; M Clo; A Oteri; S Pecchioli; I Bezemer; T Schink; S Pilgaard Ulrichsen; G Boriani; M C J Sturkenboom; F De Ponti; G Trifirò
Journal:  Eur J Clin Pharmacol       Date:  2017-08-22       Impact factor: 2.953

Review 8.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.

Authors:  Christopher Banfield; Jerry Herron; Anther Keung; Desmond Padhi; Melton Affrime
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.